Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome

Mocciaro, GabrieleD’amore, SimonaJenkins, BenjaminKay, RichardMurgia, AntonioHerrera‐marcos, Luis VicenteNeun, StefanieSowton, Alice P.Hall, ZoePalma‐duran, Susana AlejandraPalasciano, GiuseppeReimann, FrankMurray, AndrewSuppressa, PatriziaSabbà, CarloMoschetta, AntonioKoulman, AlbertGriffin, Julian L.Vacca, Michele2022-11-092022-11-092022-06-17Mocciaro, G, D’amore, S, Jenkins, B, Kay, R, Murgia, A, Herrera‐marcos, L V, Neun, S, Sowton, A P, Hall, Z, Palma‐duran, S A, Palasciano, G, Reimann, F, Murray, A, Suppressa, P, Sabbà, C, Moschetta, A, Koulman, A, Griffin, J L & Vacca, M 2022, 'Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome', International Journal of Molecular Sciences, vol. 23, no. 12, 6786. https://doi.org/10.3390/ijms231267861661-6596ORCID: /0000-0003-1336-7744/work/122953886https://hdl.handle.net/2164/19502Funding Information: G.M.: M.V., and J.L.G. were funded by the Medical Research Council (MRC) (Lipid Profiling and Signalling, MC UP A90 1006 & Lipid Dynamics and Regulation, MC PC 13030). M.V. is supported by the University of Bari (Horizon Europe Seed cod. id. S06‐miRNASH) and by the Foundation for Liver Research. G.M. was also partly funded by NIHR Cambridge Biomedical Research Centre (Gastroenterology Theme). A.K. and B.J. are supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (IS‐BRC‐1215‐20014). S.N. received a studentship from AstraZeneca. R.K. and F.R. contributions were supported by Wellcome Trust (WT220271), the BRC and the MRC (MRC_MC_UU_12012/3 and MR/M009041/1). Z.H. is supported by the Royal Society and a CAMS‐UK fellowship. A.P.S is supported by the BHF grant FS/17/61/33473. Funding Information: Funding: G.M.: M.V., and J.L.G. were funded by the Medical Research Council (MRC) (Lipid Pro‐ filing and Signalling, MC UP A90 1006 & Lipid Dynamics and Regulation, MC PC 13030). M.V. is supported by the University of Bari (Horizon Europe Seed cod. id. S06‐miRNASH) and by the Foun‐ dation for Liver Research. G.M. was also partly funded by NIHR Cambridge Biomedical Research Centre (Gastroenterology Theme). A.K. and B.J. are supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (IS‐BRC‐1215‐20014). S.N. received a stu‐ dentship from AstraZeneca. R.K. and F.R. contributions were supported by Wellcome Trust (WT220271), the BRC and the MRC (MRC_MC_UU_12012/3 and MR/M009041/1). Z.H. is supported by the Royal Society and a CAMS‐UK fellowship. A.P.S is supported by the BHF grant FS/17/61/33473. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.4495951engSubstantive connection via an eligible employment contractSDG 3 - Good Health and Well-beingLC‐MSlecithin cholesterol acyltransferase (LCAT)lipidomicslipoprotein metabolismobesityR Medicine (General)CatalysisMolecular BiologySpectroscopyComputer Science ApplicationsPhysical and Theoretical ChemistryOrganic ChemistryInorganic ChemistryR1Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic SyndromeJournal article10.3390/ijms23126786http://www.scopus.com/inward/record.url?scp=85132265887&partnerID=8YFLogxK2312